Advertisement
Advertisement
U.S. markets close in 3 hours 43 minutes
Advertisement
Advertisement
Advertisement
Advertisement

American CryoStem Corporation (CRYO)

Other OTC - Other OTC Delayed Price. Currency in USD
0.00120.0000 (0.00%)
As of 09:30AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0012
Open0.0012
Bid0.1050 x 5000
Ask1.5000 x 500
Day's Range0.0012 - 0.0012
52 Week Range0.0002 - 0.3900
Volume200
Avg. Volume1,094
Market Cap53,135
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for CRYO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AMERICAN CRYOSTEM CORPORATION
    Analyst Report: Medtronic PLCWith operational headquarters in Minnesota, Medtronic is one of the world's largest medical technology and solutions companies. Its devices focus on cardiac rhythm management, spinal and surgical navigation technologies, treatments for diabetes and neurological conditions, vascular therapies, and cardiac surgery. MDT is a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    5 hours agoArgus Research
View more
  • Newsfile

    American CryoStem Announces FDA Approval of IND to Commence Phase I Clinical Trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC)

    Eatontown, New Jersey--(Newsfile Corp. - January 6, 2023) - American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies that powers its clinical pipeline, announced today that it has received U.S. Food and Drug Administration (FDA) approval to proceed with a Phase I Clinical Trial for the treatment of Long COVID/PASC. The IND titled "A Pilot Study on Research Treatment of Lon

  • Newsfile

    American CryoStem Announces the Addition of Agustin Legido, MD, PhD, MBA to Its Advisory Board

    Eatontown, New Jersey--(Newsfile Corp. - December 22, 2022) - American CryoStem Corporation (OTC Pink: CRYO), a clinical-stage therapeutics company with a proprietary end-to-end core biotechnology platform of tissue-based cellular technologies powering its clinical pipeline, announced today that Agustin Legido, MD, PhD, MBA has joined its Scientific and Medical Advisory Board.Dr. Legido, a pediatric neurologist who holds a PhD in biochemical endocrinology, is Board Certified by the Board of Pedi

Advertisement
Advertisement